REGN vs STGW · P/E 14, rev $4.29B vs P/E 96, rev $1.49B
Regeneron Pharmaceuticals Inc (REGN) versus Stagwell Inc (STGW) — a side-by-side from cached financials, not a winner call.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Stagwell Inc (STGW) is a advertising agencies company listed on US.
Latest reported REGN revenue for 2026-06-30 was $4.29B. Net income was $1.30B. Revenue was up 19.0% from 2026-03-31 to 2026-06-30. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Latest reported STGW revenue for 2026-06-30 was $1.49B. Net income was -$21.1M. STGW currently screens at market cap $1.66B and trailing P/E 95.6.
REGN currently screens at market cap $59.10B and trailing P/E 13.9. STGW currently screens at market cap $1.66B and trailing P/E 95.6.
Not investment advice. Open the REGN and STGW stock pages for the full models.
Not investment advice.